Delisting riskPopularity #2,803
Akebia Therapeutics (AKBA)
Markets kidney-disease medicines while advancing rare-renal and HIF programs.
$0.9750
After hours+0.00 (+0.13%)
At close$0.9737(+3.75%)
Something off on this page? Send us feedback.
Next report
Nov 9, 26
in 48 days
EPS estimate
−$0.03
Revenue estimate
$46.9M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.10$0.03$0.00$0.00−$0.05−$0.03−$0.02Pending
Estimate−$0.05−$0.03−$0.02−$0.06−$0.03−$0.01−$0.04−$0.03
Surprise−100.0%+200.0%+104.6%+103.3%−66.7%−200.0%+52.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$46.5M$57.3M$62.5M$58.8M$57.6M$53.5M$49.1MPending
Estimate$37.4M$50.8M$47.9M$48.4M$46.1M$51.7M$48.9M$46.9M
Surprise+24.3%+12.9%+30.5%+21.5%+25.0%+3.6%+0.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.08 | — | — |
| Sep 2027 | −$0.08 | — | — |
| Jun 2027 | −$0.09 | — | — |
| Mar 2027 | −$0.09 | — | — |
| Dec 2026 | −$0.04 | — | — |
| Nov 2026 | −$0.03 | — | — |
| Aug 2026 | −$0.04 | −$0.02 | +52.4% |
| May 2026 | −$0.01 | −$0.03 | −200.0% |
| Feb 2026 | −$0.03 | −$0.05 | −66.7% |
| Nov 2025 | −$0.06 | $0.00 | +103.3% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.08 | — | — | $35.7M | — | — | — |
| Sep 2027 | −$0.08 | — | — | $32.9M | — | — | — |
| Jun 2027 | −$0.09 | — | — | $31.8M | — | — | — |
| Mar 2027 | −$0.09 | — | — | $28.9M | — | — | — |
| Dec 2026 | −$0.04 | — | — | $48.2M | — | — | — |
| Nov 9, 2026 | −$0.03 | — | — | $46.9M | — | — | — |
| Aug 5, 2026 | −$0.04 | −$0.02 | +52.4% | $48.9M | $49.1M | +0.6% | −26.0% |
| May 7, 2026 | −$0.01 | −$0.03 | −200.0% | $51.7M | $53.5M | +3.6% | −20.3% |
| Feb 26, 2026 | −$0.03 | −$0.05 | −66.7% | $46.1M | $57.6M | +25.0% | +9.1% |
| Nov 10, 2025 | −$0.06 | $0.00 | +103.3% | $48.4M | $58.8M | +21.5% | −18.1% |
| Aug 7, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Nov 8, 2023 | |||||||
| Aug 25, 2023 | |||||||
| May 8, 2023 | |||||||
| Mar 9, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 10, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 10, 2020 | |||||||
| May 5, 2020 | |||||||
| Mar 10, 2020 | |||||||
| Nov 12, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 9, 2019 | |||||||
| Mar 26, 2019 | |||||||
| Nov 8, 2018 | |||||||
| Aug 8, 2018 | |||||||
| May 9, 2018 | |||||||
| Mar 12, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 8, 2017 | |||||||
| May 9, 2017 | |||||||
| Mar 6, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 8, 2016 | |||||||
| May 5, 2016 | |||||||
| Mar 14, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 11, 2015 |